Cite Filings / MPLT / 0001388325-25-000021
Feed Companies Filings Check
Sign in
Cite Filings

Pages

  • Feed
  • Companies
  • Filings
  • Check a claim

Account

  • Sign in
  • Create an account
Support (opens in new tab)
SCHEDULE 13D

Beneficial Ownership Report

MapLight Therapeutics, Inc. · Filed 2025-11-04 · Acc 0001388325-25-000021

Documents 1

  • SCHEDULE 13D Beneficial Ownership Report , xslSCHEDULE_13D_X01/primary_doc.xml

Around this filing

  • 2025-11-20 SCHEDULE 13D Beneficial Ownership Report
  • 2025-11-04 SCHEDULE 13D Beneficial Ownership Report
  • 2025-10-30 4 10% owner bought 952,941 shares at $17.00 ($16,199,997)
  • 2025-10-29 4 10% owner bought 5,441,176 shares at $17.00 ($92,499,992)
  • 2025-10-29 8-K Unregistered share sale · Bylaws or fiscal year change · Other events
  • 2025-10-28 4 Chief Financial Officer acquired 43,367 shares (grant or award)
  • 2025-10-28 4 Chief Discovery Officer acquired 35,953 shares (grant or award)

Link to a passage

At least 12 characters, not counting spaces, so the link points to one passage.

External

  • SEC EDGAR (opens in new tab)

Stakes reported in this filing

Stake history · largest stake in each 13D and 13G

  1. 2026-11-16 SCHEDULE 13G/A · T. Rowe Price Investment Management, Inc. 1.7%
  2. 2026-11-16 SCHEDULE 13G/A · Forbion Growth Opportunities Fund III Cooperatief U.A. 8.4%
Loading xslSCHEDULE_13D_X01/primary_doc.xml…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…